Friday 6 November 2026
Export BDX’s income statement to Excel — free account
Becton, Dickinson and Company
BDX Healthcare Medical Instruments & Supplies
Becton, Dickinson and Company’s revenue for fiscal 2025 (year ended September 2025) was $21.8 billion, up 8.24% from fiscal 2024.
- Revenue
- −9.55%
- EPS
- −31.5%
- Free cash flow
- −31.6%
- Total debt
- −22.9%
Quarter to June 2026, against a year earlier
213.91
0.36
+0.17%
Follow BDX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
45.58 | 39.81 | 25.34 | 25.65 |
+8 more quarters Free account |
P/S ratio |
2.00 | 2.07 | 2.02 | 1.97 | |
P/FCF ratio |
12.98 | 12.63 | 16.86 | 16.14 | |
P/Operating CF |
53.59 | 65.76 | 67.51 | 23.27 | |
P/B ratio |
1.70 | 1.83 | 1.75 | 1.70 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.60 | 2.71 | 2.75 | 2.74 | |
EV/EBITDA |
11.39 | 11.92 | 11.71 | 11.89 | |
EV/Operating CF |
13.71 | 13.54 | 17.75 | 17.47 | |
EV/FCF |
16.93 | 16.54 | 22.90 | 22.44 | |
Quick Ratio |
0.34 | 0.38 | 0.40 | 0.38 | |
Current Ratio |
0.87 | 0.94 | 1.05 | 1.11 | |
Net Debt/EBITDA |
10.32 | 22.33 | 13.63 | 9.58 | |
Debt/Assets |
26.63% | 28.93% | 30.85% | 31.85% | |
Debt/Equity |
0.55 | 0.61 | 0.67 | 0.69 | |
Asset Turnover |
0.39 | 0.41 | 0.40 | 0.39 | |
Operating CF/Net income |
2.06 | (2.16) | 1.72 | 3.76 | |
Capex/Depreciation |
(0.25) | (0.24) | (0.18) | (0.50) | |
Interest Coverage |
5.02 | 0.62 | 3.60 | 6.42 | |
Research and Development Expense of Revenue |
5.18% | 5.28% | 5.83% | 7.81% | |
Selling, General and Administrative Expense of Revenue |
25.31% | 25.73% | 26.52% | 28.52% | |
Intangible Assets out of Total Assets |
0.67 | 0.67 | 0.65 | 0.64 | |
Share Based Compensation of Revenue |
1.10% | 1.23% | 1.73% | 1.34% | |
Graham Net Nets |
(0.44) | (0.42) | (0.46) | (0.48) | |
Graham Number |
81.47 | 87.42 | 110.50 | 107.70 | |
Earnings Yield |
2.19% | 2.51% | 3.95% | 3.90% | |
Free Cash Flow Yield |
7.70% | 7.92% | 5.93% | 6.20% | |
Revenue per Share |
18.13 | 16.80 | 18.39 | 20.48 | |
Operating CF per Share |
2.82 | 2.39 | 2.30 | 6.44 | |
Capex per Share |
(0.52) | (0.45) | (0.38) | (1.31) | |
Free Cash Flow per Share |
2.30 | 1.95 | 1.92 | 5.13 | |
Cash per Share |
3.14 | 3.63 | 3.62 | 2.73 | |
Shareholders Equity per Share |
88.85 | 85.99 | 88.53 | 88.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
88.85 | 85.99 | 88.53 | 88.27 | |
Free Cash Flow |
633.00 | 546.00 | 549.00 | 1,475.00 | |
Working Capital |
(1,265.00) | (495.00) | 428.00 | 942.00 | |
Capital Expenditures |
(143.00) | (125.00) | (108.00) | (377.00) | |
Net Current Asset Value |
(18,176.00) | (18,687.00) | (20,370.00) | (20,680.00) | |
EV/EBIT |
23.50 | 24.25 | 22.52 | 23.24 | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.06 | |
Price to Operating Income |
18.02 | 18.51 | 16.58 | 16.71 | |
| Other line items | |||||
Average Receivables |
2,653.50 | 2,617.00 | 2,573.00 | 2,714.50 | |
Average Payables |
6,228.50 | 6,010.50 | 6,242.50 | 4,001.00 | |
Average Inventory |
3,632.50 | 3,540.00 | 3,972.50 | 3,496.00 | |
Average Assets |
52,816.50 | 52,649.50 | 54,753.00 | 56,305.50 | |
Average Common Equity |
24,944.50 | 24,686.50 | 25,243.00 | 25,639.50 |
Columns are period end dates · fundamentals updated 26 Oct 2026